AI-powered
podcast player
Listen to all your favourite podcasts with AI-powered features
Tarlatumab Approval: Insights from the Delphi 301 Study
This chapter covers the recent approval of Tarlatumab, a bispecific T cell engager, focusing on its clinical trial results from the Delphi 301 study. With a reported response rate of 40% and critical metrics like duration of response and median overall survival, the chapter also examines the dosing strategies and comparisons within the trial.